Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05222932 · ClinicalTrials.gov registry record · Phase 1
Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1
A Phase 1 study of Melanoma and Head and Neck Squamous Cell Carcinoma, sponsored by TILT Biotherapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT05222932: Active Phase 1 study of Melanoma and Head and Neck Squamous Cell Carcinoma, sponsored by TILT Biotherapeutics.
NCT05222932 is a Phase 1 study of Melanoma and Head and Neck Squamous Cell Carcinoma that is active but no longer recruiting, run by TILT Biotherapeutics. The registered enrollment target is 15 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05222932, a Phase 1 study of Melanoma and Head and Neck Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by TILT Biotherapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase 1, dose-escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with avelumab in patients with advanced solid tumors refractory to or progressing after anti-PD(L)1.
Primary Outcome
Safety I
Conditions Studied
Interventions
- BIOLOGICAL TILT-123
- DRUG Avelumab
Study Locations (2)
New York
- Memorial Sloan Kettering Cancer Center - New York
Other
- Docrates Cancer Center - Helsinki
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-03-08 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What the registry record for NCT05222932 still lists
NCT05222932 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which TILT-123 is the first listed.
NCT05222932 reports a single indexed study location in New York, Other.
Frequently Asked Questions
What is clinical trial NCT05222932 about?
NCT05222932 is a clinical study titled "Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1". This is a phase 1, dose-escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with avelumab in patients with advanced solid tumors refractory to or progressing after anti-PD(L)1.
What is the current status of trial NCT05222932?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2023-03-08. Estimated completion is 2026-12.
What conditions does trial NCT05222932 study?
This clinical trial studies the following conditions: Melanoma, Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05222932?
The interventions under investigation include: TILT-123 (BIOLOGICAL), Avelumab (DRUG).
Who is sponsoring clinical trial NCT05222932?
This trial is sponsored by TILT Biotherapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05222932 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05222932's enrollment target sits among peer trials
15 241st of 266 higher than 24 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI